Tue. 9 Apr 2024, 4:02pm ET
Benzinga
Biotech, News, General
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor
Corvus anticipates releasing initial clinical data from trial before year-end 2024